Plasma metabolomics in male primary and functional hypogonadism.
hypogonadism
markers
metabolomics
proteomics
testosterone
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
02
2023
accepted:
01
05
2023
medline:
20
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Metabolomics proposes to unveil the molecular machinery involved in each specific disease by the comprehensive analysis of low-molecular-weight metabolites in a biological sample. This narrative mini-review analyzes previous studies applying ultra-high-performance liquid chromatography-high-resolution mass spectrometry (HRMS)-based metabolomics to highlight different metabolic pathways involved in male hypogonadism and testosterone replacement therapy, both in the case of insulin-sensitive patients with primary hypogonadism and in the case of insulin-resistant patients with functional hypogonadism. In functional hypogonadism, metabolomics revealed that different biochemical pathways are affected. In detail, glycolysis is the most important biochemical process involved in these patients. Glucose metabolism is fueled by amino acid degradation, and gluconeogenesis is widely stimulated. Some important pathways, including glycerol, are compromised. Furthermore, mitochondrial electron transport is influenced, namely, by a decrease in ATP production. On the contrary, beta-oxidation of short- and medium-chain fatty acids does not represent an energy source in hypogonadal patients. Both lactate and acetyl-CoA are converted into ketone bodies, which increased immensely. However, carnosine and β-alanine are greatly reduced. These metabolic changes are associated with increased fatigue and mental confusion. After testosterone replacement therapy, a complete restoration is achieved for only a part of the metabolites. It is of note that only in patients with functional hypogonadism treated with testosterone are ketone bodies produced at high levels, so the symptoms sometimes reported by these patients after the beginning of the therapy (difficulty in concentrating, depressed mood, brain fog, and memory impairment) might represent a specific "keto flu-like" syndrome, related to the metabolic ketonic state.
Identifiants
pubmed: 37334300
doi: 10.3389/fendo.2023.1165741
pmc: PMC10273261
doi:
Substances chimiques
Testosterone
3XMK78S47O
Insulin
0
Ketone Bodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165741Informations de copyright
Copyright © 2023 Grande, De Toni, Garolla, Milardi and Ferlin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Endocrinol. 2013 Feb 20;168(3):445-55
pubmed: 23425925
Cell Death Dis. 2018 Apr 22;9(6):671
pubmed: 29867095
J Endocrinol Invest. 2022 May;45(5):911-926
pubmed: 35041193
Cell Death Dis. 2018 Apr 22;9(6):653
pubmed: 29844353
Hum Genet. 2021 Jan;140(1):77-111
pubmed: 32200437
J Clin Endocrinol Metab. 2017 Mar 1;102(3):1067-1075
pubmed: 28359097
Protein Pept Lett. 2020;27(12):1186-1191
pubmed: 32370701
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
Andrology. 2020 Nov;8(6):1519-1529
pubmed: 31502758
Andrology. 2017 May;5(3):408-413
pubmed: 28267892
J Sex Med. 2014 Mar;11(3):840-56
pubmed: 24308723
J Endocrinol Invest. 2022 Dec;45(12):2385-2403
pubmed: 36018454
J Clin Endocrinol Metab. 2015 Aug;100(8):3172-82
pubmed: 26000545
Diabetes Care. 2011 Apr;34(4):828-37
pubmed: 21386088
Clin Endocrinol (Oxf). 2011 Mar;74(3):377-83
pubmed: 21118287
Int J Endocrinol. 2015;2015:294278
pubmed: 26491440
Int J Mol Sci. 2022 Jul 14;23(14):
pubmed: 35887101
Clin Endocrinol (Oxf). 2018 Jul;89(1):11-21
pubmed: 29683196
J Cell Mol Med. 2020 Jul;24(14):8266-8269
pubmed: 32491269
Andrology. 2020 Sep;8(5):970-987
pubmed: 32026626